ArticleIBRO neuroscience reports2026
Patterns of motor nerve demyelination and their prognostic significance in multifocal motor neuropathy.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multifocal motor neuropathy (MMN) is a rare immune-mediated neuropathy characterized by motor nerve involvement and, typically, a good response to intravenous immunoglobulin (IVIg). However, a subgroup of patients shows poor or absent treatment response and a more rapid disease course. We aim to characterize clinical, laboratory, and electrophysiological features associated with IVIg response in MMN over a follow-up period of up to 20 years. Methods: Thirteen patients fulfilling diagnostic criteria for definite MMN were retrospectively analyzed. Detailed clinical data, comorbidities, IVIg treatment regimens, and serial nerve conduction studies (NCS) were evaluated. Particular attention was given to the extent and distribution of conduction block (CB) and temporal dispersion (TD). IVIg response was defined as ≥ 1-point improvement in MRC strength in at least two muscle groups within 4 weeks after infusion or equivalent functional improvement documented in medical records. Results: Four of 13 patients (31%) showed poor or absent IVIg response. These patients exhibited a higher number of clinically and electrophysiologically affected motor nerves at disease onset (median 6 vs. 3, p = 0.014) and more nerves with TD (median 2.5 vs. 1, p = 0.025), compared to IVIg responders. CB alone did not reliably distinguish responders from non-responders (median 1 vs. 1, p = 0.74). Anti-GM1 IgM antibodies were detected in 44% of the patients tested, of whom 75% were non-responders. Comorbidities (e.g., diabetes II, malignancy, autoimmune disease) were more frequent among non-responders. Conclusions: A pattern of early nerve involvement with prominent TD appears to be associated with a more aggressive disease course and poorer IVIg response. Diagnostic evaluation in MMN should not focus solely on focal CB but also systematically assess the number of nerves with TD. Prospective studies with standardized protocols are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.